ArticleDiabetes2013
Altered response of skeletal muscle to IL-6 in type 2 diabetic patients.
Article in Diabetes, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 62 citations in OpenAlex.
- Effects of a Circuit Training Program on Myokine Levels in Insulin-Resistant Women: A Randomised Controlled Trial.Journal of diabetes research · 2024Trial
- Blocking endogenous IL-6 impairs mobilization of free fatty acids during rest and exercise in lean and obese men.Cell reports. Medicine · 2021Trial
- Growth and differentiation factor 15 is secreted by skeletal muscle during exercise and promotes lipolysis in humans.JCI insight · 2020Trial
- The Dual Role of Interleukin-6 in the Pathophysiology of Skeletal Muscle: Mechanisms, Challenges, and Therapeutic Prospects.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Sarcopenia and body temperature-the significance of interorgan metabolic networks in skeletal muscle atrophy.Endocrine journal · 2026Review
- Physical activity is associated with improved glycemic control but not with IL-6-glycemic interactions in type 2 diabetes: a cross-sectional study.Frontiers in endocrinology · 2026Observational
- Inflammation-Insulin Resistance Crosstalk and the Central Role of Myokines.International journal of molecular sciences · 2025Review
- Exercise-Induced Muscle-Fat Crosstalk: Molecular Mediators and Their Pharmacological Modulation for the Maintenance of Metabolic Flexibility in Aging.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Article
- Myokines as potential mediators of changes in glucose homeostasis and muscle mass after bariatric surgery.Frontiers in endocrinology · 2025Review
- Suppression of gp130 attenuated insulin-mediated signaling and glucose uptake in skeletal muscle cells.Scientific reports · 2024Article
- IL-6 and diabetic kidney disease.Frontiers in immunology · 2024Review
- Preliminary study on the effect of ozone exposure on blood glucose level in rats.Technology and health care : official journal of the European Society for Engineering and Medicine · 2023Article
- Review
- Mechanisms by Which Skeletal Muscle Myokines Ameliorate Insulin Resistance.International journal of molecular sciences · 2022Review
- Potential Mechanisms for How Long-Term Physical Activity May Reduce Insulin Resistance.Metabolites · 2022Review
- The bidirectional relationship between AMPK pathway activation and myokine secretion in skeletal muscle: How it affects energy metabolism.Frontiers in physiology · 2022Review
- The effect of toll-like receptor ligands on energy metabolism and myokine expression and secretion in cultured human skeletal muscle cells.Scientific reports · 2021Article
- Insulin Downregulated the Infection of UropathogenicMicroorganisms · 2021Article
- Histone deacetylase 5 regulates interleukin 6 secretion and insulin action in skeletal muscle.Molecular metabolism · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-6 (IL-6) has a dual role in modulating insulin sensitivity, with evidence for this cytokine as both an enhancer and inhibitor of insulin action. We determined the effect of IL-6 exposure on glucose and lipid metabolism in cultured myotubes established from people with normal glucose tolerance or type 2 diabetes. Acute IL-6 exposure increased glycogen synthesis, glucose uptake, and signal transducer and activator of transcription 3 (STAT3) phosphorylation in cultured myotubes from normal glucose tolerant subjects. However, in type 2 diabetic patients, IL-6 was without effect on glucose metabolism and STAT3 signaling, concomitant with increased suppressor of cytokine signaling 3 (SOCS3) expression. IL-6 increased fatty acid oxidation in myotubes from type 2 diabetic and normal glucose tolerant subjects. Expression of IL-6, IL-6 receptor (IL-6R), or glycoprotein 130, as well as IL-6 secretion, was unaltered between cultured myotubes from normal glucose tolerant or type 2 diabetic subjects. Circulating serum IL-6 concentration was unaltered between normal glucose tolerant and type 2 diabetic subjects. In summary, skeletal muscle cells from type 2 diabetic patients display selective IL-6 resistance for glucose rather than lipid metabolism. In conclusion, IL-6 appears to play a differential role in regulating metabolism in type 2 diabetic patients compared with normal glucose tolerant subjects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.